Clinical Trial

Effects of Acetyl L-Carnitine Supplementation on Clinical, Metabolic and Inflammatory Symptoms in Obese, Diabetic, Postmenopausal Women With Osteoarthritis

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 22, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
OA is a degenerative bone disease more common in postmenopausal women. Diabetes and obesity are common risk factors for the development of OA. The common symptoms include pain and disability of the affected joint, leading to mobility issues. Acetyl L-carnitine due to its known anti-inflammatory, chondroprotective, and improved insulin-sensitizing effects may help in alleviating the symptoms and progression of OA in obese diabetic postmenopausal women.
Trial Details
NCT Number NCT07660081
Lead Sponsor Khyber Medical University Peshawar
Conditions Osteoarthritis, Type 2 Diabetes, Obesity
Enrollment 100 participants
Start Date 2025-11-01
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-22